Expertise in

conditions

Roberto Giugliani

Porto Alegre, RS, BR

Expertise in

conditions

Porto Alegre, RS, BR

Overview

Roberto Giugliani practices practicing medicine in Porto Alegre, Brazil.

Mr. Giugliani is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Acid Sphingomyelinase Deficiency (ASMD), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 374 peer reviewed articles and participating in 19 clinical trials.

Gender

Male

Locations

Porto Alegre, RS, Brazil

Other Locations

Sao Paulo, SP 06455010, Brazil

Rio Grande, RS, Brazil

Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy

Enrollment Status: Completed

Publish Date: July 10, 2026

Intervention Type: Drug

Study Drug: SHP611

Study Phase: Phase 2

A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Intracisternal RGX-111 Gene Therapy in Participants With Mucopolysaccharidosis Type I

Enrollment Status: Suspended

Publish Date: March 12, 2026

Intervention Type: Genetic

Study Phase: Phase 1/Phase 2

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway

Enrollment Status: Terminated

Publish Date: January 28, 2026

Intervention Type: Drug

Study Drug: Venglustat GZ402671

Study Phase: Phase 3

Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients

Enrollment Status: Completed

Publish Date: October 24, 2025

A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2025

Intervention Type: Genetic

Study Phase: Phase 2/Phase 3

A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease

Enrollment Status: Terminated

Publish Date: June 17, 2024

Intervention Type: Drug

Study Drug: Replagal

Study Phase: Phase 3

Biomarker for Gilbert Disease - An International, Multi- Center, Epidemiological Protocol

Enrollment Status: Withdrawn

Publish Date: February 13, 2023

Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study

Enrollment Status: Withdrawn

Publish Date: February 13, 2023

Biomarkers for Hunter Syndrome: An International, Multicenter, Observational, Longitudinal Protocol

Enrollment Status: Terminated

Publish Date: February 10, 2023

A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI

Enrollment Status: Unknown

Publish Date: December 19, 2022

Intervention Type: Drug

Study Drug: Losartan

Study Phase: Phase 2

View 9 Less Clinical Trials

374 Total Publications

Thirty-three years of X-linked adrenoleukodystrophy diagnosis at a Brazilian reference center: diagnostic patterns and key findings.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: July 23, 2026

View All 374 Publications

Frequently Asked Questions about Roberto Giugliani

Is Roberto Giugliani a top-rated expert for Mucopolysaccharidoses (MPS)?

MediFind is an objective health platform that identifies experts based on real-world data. Roberto Giugliani is classified as an Elite expert for Mucopolysaccharidoses (MPS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Roberto Giugliani participate in research or clinical trials?

Yes. Roberto Giugliani has published 374 articles and abstracts on conditions like Mucopolysaccharidoses (MPS). You can view a list of Roberto Giugliani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Giugliani's expertise for a condition

ConditionClose